










Study with the several resources on Docsity
Earn points by helping other students or get them with a premium plan
Prepare for your exams
Study with the several resources on Docsity
Earn points to download
Earn points by helping other students or get them with a premium plan
Community
Ask the community for help and clear up your study doubts
Discover the best universities in your country according to Docsity users
Free resources
Download our free guides on studying techniques, anxiety management strategies, and thesis advice from Docsity tutors
SOCRA CCRP Exam ACTUAL EXAM QUESTIONS & Verified ANSWERS WITH RATIONALES 2025 GRADED A+.pdf
Typology: Exams
1 / 18
This page cannot be seen from the preview
Don't miss anything!
When there is no additional relevant information to provide to the subject? - ANSWhen is the informed consent process over? Varied backgrounds, diversity and expertise Upon earlier notification, investigations may begin - ANSHow long does it take for an IND to go into effect? (21 CFR Part 312) Uncontrolled (Long term expansion studies) - ANS5 Common Study Designs Unapproved drug to be shipped lawfully for the purpose of conducting investigations of the drug - ANSAn IND permits what? (21 CFR Part 312) Unanticipated adverse device effect (UADE) - ANSWhat is the SAE counterpart in device trials? Triggered by NDA - ANSHow are study oriented FDA Inspections classified? Triggered by data issue, complaint from study subject/staff, publication of results from an ongoing study - ANSHow are investigator oriented FDA inspections classified? To safeguard rights, safety and well being of all trial subjects To pay special attention to trials that may include vulnerable subjects - ANSWhat are the goals of an IRB? (21 CFR Part 56) The subject only - ANS21 CFR Part 50 only requires who to sign the ICF? The sponsor, the IRB evaluates the determination - ANSWho makes the initial determination of SR or NSR? the shipment of a device for the purpose of conducting investigations of the device without complying without FDA requirements that would apply to devices in commercial distribution - ANSWhat does an Investigational Device Exemption (IDE) permit? The probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological exams and tests - ANSIRB definition of Minimal Risk The Informed Consent Process - ANSWhen does the subject have the right to ask questions about the study? The Informed Consent Form - ANSWhat cannot include language that releases or appears to release investigator, institution, sponsor or their agents from liability for negligence? The Informed Consent Form - ANSWhat cannot contain language that waives or appears to waive the rights of the subject? The FDA - ANSWho determines if Phase II/III studies are likely to yield data capable of meeting regulatory standards for marketing approval? temperature - ANSCore Battery for Central Nervous System Table of Contents surgical drapes - ANSExamples of Class II devices Subjects may not be given the investigational drug - ANSWhat does a FDA "Clinical Hold" mean for a proposed study?
Subject and person conducting the consent process - ANSICH E6 guidelines requires who to sign the ICF? Study that investigates the mode of action and/or effects of a drug substance in relation to its desired therapeutic target - ANSPrimary Pharmacodynamic Studies Study Oriented Studies that investigate the potential undesirable PD effects of a substance on physiological functions in relation to exposure in the therapeutic range or above - ANSSafety Pharmacology Studies (Pre-Clinical) Studies that investigate the mode of action and/or effects of a drug substance not related to its desire therapeutic target - ANSSecondary Pharmacodynamic Studies Sponsor Medical Monitor - ANSWho is responsible for clinical oversight, evaluating safety information-trial wide? Sponsor - ANSWho is responsible with providing pre-clinical and clinical study reports in the information amendments to the IND? Sponsor - ANSWho is responsible to terminate all studies if the product presents an unreasonable and significant risk to study subjects? Sponsor - ANSWho is responsible fore maintaining an effective IND or IDE? Sponsor - ANSWho is responsible for submitting safety reports to sites? Sponsor - ANSWho is responsible for selecting qualified monitors? Sponsor - ANSWho is responsible for selecting qualified investigators? Sponsor - ANSWho is responsible for promptly reporting information about significant new adverse events or unanticipated adverse device effect with respect to the investigational product? Sponsor - ANSWho is responsible for ensuring all investigators are conducting studies according to the general investigational plan and protocols in the IND? Sponsor - ANSWho is required to notify all parties involved, if warranted, of new safety information adversely affecting subject safety? Sponsor - ANSWho has the responsibility to obtain an agreement from the investigator to adhere to the protocol, obtain IRB approval and GCP compliance? Sponsor - ANSWho has the responsibility to ensure the study is designed by qualified individuals? Sponsor - ANSWho has the responsibility in submitting an annual report to the IND/IDE? Sponsor - ANSWho has the responsibility in maintaining quality assurance and quality control systems, with SOPs, for all activities? Sponosr - ANSWho is responsible for providing information needed to conduct the study?
Powered wheel chairs Placebo controlled Pivotal Study - ANSTypes of Device Trials Pilot Study Phase III - ANSWhat phase of study usually has the largest number of subjects per study? Phase II/III - ANSWhat phases of stuides are usually multicenter? Phase II/ III trials or Phase II and III - ANSThese phase of trials, the FDA helps assure the quality of the scientific evaluation is adequate to permit evaluation of the drugs safety and efficacy ( CFR Part 312) Phase I - ANSWhat phase of study is usually single-center? pharm and tox information Parallel Group (efficacy and safety) On-Site Monitors - ANSWho is responsible for periodic site visits? no-treatment concurrent control Not less than once a year Non-significant risk trials - ANSWhat type of device studies are subject to abbreviated IDE regulations? (21 CFR Part 812.2b) No white-Out - ANSHow should source document corrections be made according to GCP guidelines? no new subjects may be given the IP and subjects already taking the drug should be discontinued unless continuation is specifically permitted by the FDA - ANSWhat does a FDA "Clinical Hold" mean for an ongoing study? No erasures New Drug Application - ANS21 CFR 314 Need for investigational drug arises in an emergency situation Multidisciplinary - ANSICH M Motor activity Monitor Responsibilties - ANSICH E6, Section 5. Moderate risk, usually requires 510k, might require PMA - ANSHow do you define a device with Class II risk? Medical Device Reporting - ANS21 CFR Part 803 Medical Device Classification Procedures - ANS21 CFR Part 860 Make study records available for inspection - ANS21 CFR Part 312. Maintain adequate and accurate records Lowest Risk, 510K often not required - ANSHow do you define Class I Devices? investigator's brochure Investigator responsibilitiy - ANS21 CFR Part 312. Investigator Responsibilities - ANSICH E6 Section 4 Investigator Responsibilities - ANS21 CFR 312.60- 70 Investigator Oriented - ANSWhat are the two types of FDA Inspections?
Investigational New Drug Application Investigational Device Exemption - ANS21 CFR Part 812 Investigational Device Exemption - ANS21 CFR 812 Investigational agreement - ANSWhat is used in device studies instead of a 1572? Introductory statement Interventions designed solely to enhance well-being of the patient with reasonable expectation of success - ANSHow does the Belmont Report Define "Practice"? Insufficient time to allow for submission of an IND or a treatment IND Institutional Review Board - ANS21 CFR Part 56 Initial and date the change infusion pumps Informed consent - ANSWhat must be obtained from the subject or LAR prior to initiating any research related exams? Informed Consent - ANSICH E6 Section 4. Informed Consent - ANS21 CFR Part 50 IND Application - ANS21 CFR 312 implanted cerebella stimulators implantable pacemakeres - ANSExamples of Class III Drugs Immediately - ANSWhen do SAEs need to be reported to Sponsors? If the research is funded in whole or part by HHS and regulated by the FDA - ANSWhen is research regulated by both FDA and HHS? If the changes in the research trial affect the treatment of the subject, or may affect the subject's willingness to continue in the study - ANSWhen must patient's be reconsented? Identification and correction - ANSWhat does QC focus on? historical control - ANSWhat type of controls are commonly used in patient trials? Highest risk, PMA required - ANSHow do you define a device with Class III risk? HHS Regulations for Protection of Human Subjects - ANS45 CFR Part 46 Heart Rate Health and Human Services - ANSHow is HHS defined? guidance for industry, consolidated guideance - ANSICH E 6 General Investigational Plan Functional Assessments (tidal volume, hgb Oxygen saturation) - ANSCore Battery for Respiratory System Form 483 - ANSWhat is the FDA form for issuing summary of observations during an inspection? Form 482 - ANSWhat is the FDA Inspection Form? For Cause or Directed Financial Disclosures - ANS21 CFR Part 54 FDA - ANSBefore clinical trials can be initiated, an application containing the appropriate information must be submitted to regulatory authorities, in the USA this is called XXXX and submitted to the XXX (21 CFR Part 312)
Blinding - ANSWhat is used to minimize potential subconscious bias in evaluating treatment response? behavioral changes Be supported by additional information such as animal studies and other human studies
6)significant new finding statement - ANSWhat additional elements can be included in an ICF, but not required? 6)significant findings and corrective action - ANSWritten monitoring reports should include what elements? 6)humanitarian Benefits outweigh risk
3)Maintain drug and device accountability records from manufacturing through use, return and destruction - ANSWhat are SPONSOR responsibilities with regard to IP? 3)Justice - ANSWhat are the three principles of the Belmont Report? 3)is of substantial importance in diagnosing, curing, mitigating or treating disease or other prevents impairment of human health 3)Investigator's brochure is misleading, inaccurate or materially incomplete 3)Handicapped 3)Does not require invasive sampling procedure 3)Control the use of investigational product - ANSWhat are three primary responsibility of investigators? 3)CNS - ANSThree vital organ considered highest priority 3)and IRB approved written summary of what is to be said to the participant or LAR 3)All drug returned to the sponsor or destroyed as directed by sponsor 3)additional costs
2 )Life-threatening 2)is used in supporting or sustaining life 2)if that effect, problem, or death was not previously identified in nature, severity, or degree of incidence in the investigational plan or application 2)Extent the drug has been studied previously 2)diagnostic device complying with labeling requirements, testing is non-invasive 2)CV 2)Clinical investigators are not qualified 2)Benefit of research not restricted to those who can afford it
$50,000 - ANSWhat is the $ reported amount for a financial disclosure for equity interest in a publicly traded company? $25,000 - ANSWhat is the $ reported amount for a financial disclosure for significant payments?